Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1992 Mar;140(3):629–637.

Induction in mice of human light-chain-associated amyloidosis.

A Solomon 1, D T Weiss 1, M B Pepys 1
PMCID: PMC1886151  PMID: 1546744

Abstract

Primary (idiopathic) or multiple myeloma-associated amyloidosis is characterized by the deposition in tissue of monoclonal light chains or light-chain fragments (AL amyloidosis). In contrast to other types of amyloidosis, information regarding the pathogenesis of light-chain-related amyloid has heretofore been limited due to the lack of a suitable in vivo model. The authors report the successful experimental induction of human AL amyloid deposits. The repeated injection into mice of Bence Jones proteins obtained from two patients with AL amyloidosis produced the histopathologic lesions characteristic of this disease. Partial dehydration of animals before protein injection resulted in the acceleration of amyloid formation. The human proteins were deposited as amyloid within the mouse renal blood vessel walls and parenchymal tissue, as well as in other organs. The deposits were Congo red-positive, exhibited green birefringence, and had a fibrillar ultrastructure. As evidenced immunohistochemically, the experimentally induced amyloid deposits consisted of the injected human light chains, and in addition, contained mouse amyloid P component (AP); mouse immunoglobulin (Ig) or inflammatory-associated amyloid A protein was not detected. Extraction and characterization of the amyloid deposits found within the mouse kidney revealed the presence of a predominantly intact human light polypeptide chain. Mice injected in identical manner with a non-amyloid-associated Bence Jones protein had no or only rare amyloid deposits. The experimental mouse model provides a means to ascertain the amyloidogenic potential of human monoclonal light chains and to study further the pathogenesis of AL amyloidosis.

Full text

PDF
629

Images in this article

632Figure 1
on p.632
632Figure 3
on p.632
632Figure 4
on p.632
633Figure 2
on p.633
634Figure 5
on p.634
635Figure 6
on p.635

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Axelrad M. A., Kisilevsky R., Willmer J., Chen S. J., Skinner M. Further characterization of amyloid-enhancing factor. Lab Invest. 1982 Aug;47(2):139–146. [PubMed] [Google Scholar]
  2. Baltz M. L., Caspi D., Evans D. J., Rowe I. F., Hind C. R., Pepys M. B. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol. 1986 Dec;66(3):691–700. [PMC free article] [PubMed] [Google Scholar]
  3. Baltz M. L., Gomer K., Davies A. J., Evans D. J., Klaus G. G., Pepys M. B. Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains. Clin Exp Immunol. 1980 Feb;39(2):355–360. [PMC free article] [PubMed] [Google Scholar]
  4. Bellotti V., Merlini G., Bucciarelli E., Perfetti V., Quaglini S., Ascari E. Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Br J Haematol. 1990 Jan;74(1):65–69. doi: 10.1111/j.1365-2141.1990.tb02539.x. [DOI] [PubMed] [Google Scholar]
  5. Benson M. D., Dwulet F. E., Madura D., Wheeler G. Amyloidosis related to a lambda IV immunoglobulin light chain protein. Scand J Immunol. 1989 Feb;29(2):175–179. doi: 10.1111/j.1365-3083.1989.tb01114.x. [DOI] [PubMed] [Google Scholar]
  6. Buxbaum J. Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture. J Clin Invest. 1986 Sep;78(3):798–806. doi: 10.1172/JCI112643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dische F. E., Wernstedt C., Westermark G. T., Westermark P., Pepys M. B., Rennie J. A., Gilbey S. G., Watkins P. J. Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia. 1988 Mar;31(3):158–161. doi: 10.1007/BF00276849. [DOI] [PubMed] [Google Scholar]
  8. Epstein W. V., Tan M., Wood I. S. Formation of "amyloid" fibrils in vitro by action of human kidney lysosomal enzymes on Bence Jones proteins. J Lab Clin Med. 1974 Jul;84(1):107–110. [PubMed] [Google Scholar]
  9. Eulitz M., Breuer M., Linke R. P. Is the formation of AL-type amyloid promoted by structural peculiarities of immunoglobulin L-chains? Primary structure of an amyloidogenic lambda-L-chain (BJP-ZIM). Biol Chem Hoppe Seyler. 1987 Jul;368(7):863–870. doi: 10.1515/bchm3.1987.368.2.863. [DOI] [PubMed] [Google Scholar]
  10. Eulitz M., Linke R. Amyloid fibrils derived from V-region together with C-region fragments from a lambda II-immunoglobulin light chain (HAR). Biol Chem Hoppe Seyler. 1985 Sep;366(9):907–915. doi: 10.1515/bchm3.1985.366.2.907. [DOI] [PubMed] [Google Scholar]
  11. Glenner G. G. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med. 1980 Jun 5;302(23):1283–1292. doi: 10.1056/NEJM198006053022305. [DOI] [PubMed] [Google Scholar]
  12. Glenner G. G., Ein D., Eanes E. D., Bladen H. A., Terry W., Page D. L. Creation of "amyloid" fibrils from Bence Jones proteins in vitro. Science. 1971 Nov 12;174(4010):712–714. doi: 10.1126/science.174.4010.712. [DOI] [PubMed] [Google Scholar]
  13. Glenner G. G., Terry W., Harada M., Isersky C., Page D. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science. 1971 Jun 11;172(3988):1150–1151. doi: 10.1126/science.172.3988.1150. [DOI] [PubMed] [Google Scholar]
  14. Hawkins P. N., Lavender J. P., Pepys M. B. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990 Aug 23;323(8):508–513. doi: 10.1056/NEJM199008233230803. [DOI] [PubMed] [Google Scholar]
  15. Hawkins P. N., Myers M. J., Epenetos A. A., Caspi D., Pepys M. B. Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med. 1988 Mar 1;167(3):903–913. doi: 10.1084/jem.167.3.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hawkins P. N., Wootton R., Pepys M. B. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest. 1990 Dec;86(6):1862–1869. doi: 10.1172/JCI114917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Isobe T., Osserman E. F. Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases. Ann N Y Acad Sci. 1971 Dec 31;190:507–518. doi: 10.1111/j.1749-6632.1971.tb13560.x. [DOI] [PubMed] [Google Scholar]
  18. Isobe T., Osserman E. F. Patterns of amyloidosis and their association with plasma-cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins. N Engl J Med. 1974 Feb 28;290(9):473–477. doi: 10.1056/NEJM197402282900902. [DOI] [PubMed] [Google Scholar]
  19. Kisilevsky R., Boudreau L. Kinetics of amyloid deposition. I. The effects of amyloid-enhancing factor and splenectomy. Lab Invest. 1983 Jan;48(1):53–59. [PubMed] [Google Scholar]
  20. Koss M. N., Pirani C. L., Osserman E. F. Experimental Bence Jones cast nephropathy. Lab Invest. 1976 Jun;34(6):579–591. [PubMed] [Google Scholar]
  21. Linke R. P., Zucker-Franklin D., Franklin E. D. Morphologic, chemical, and immunologic studies of amyloid-like fibrils formed from Bence Jones Proteins by proteolysis. J Immunol. 1973 Jul;111(1):10–23. [PubMed] [Google Scholar]
  22. OSSERMAN E. F., TAKATSUKI K., TALAL N. MULTIPLE MYELOMA I. THE PATHOGENESIS OF "AMYLOIDOSIS. Semin Hematol. 1964 Jan;1:3–85. [PubMed] [Google Scholar]
  23. Pepys M. B. Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology. 1979 Jul;37(3):637–641. [PMC free article] [PubMed] [Google Scholar]
  24. Pras M., Schubert M., Zucker-Franklin D., Rimon A., Franklin E. C. The characterization of soluble amyloid prepared in water. J Clin Invest. 1968 Apr;47(4):924–933. doi: 10.1172/JCI105784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Shirahama T., Benson M. D., Cohen A. S., Tanaka A. Fibrillar assemblage of variable segments of immunoglobulin light chains: an electron microscopic study. J Immunol. 1973 Jan;110(1):21–30. [PubMed] [Google Scholar]
  26. Solomon A., Frangione B., Franklin E. C. Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest. 1982 Aug;70(2):453–460. doi: 10.1172/JCI110635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Solomon A. Light chains of human immunoglobulins. Methods Enzymol. 1985;116:101–121. doi: 10.1016/s0076-6879(85)16008-8. [DOI] [PubMed] [Google Scholar]
  28. Solomon A. Light chains of immunoglobulins: structural-genetic correlates. Blood. 1986 Sep;68(3):603–610. [PubMed] [Google Scholar]
  29. Solomon A., McLaughlin C. L. Bence-Jones proteins and light chains of immunoglobulins. I. Formation and characterization of amino-terminal (variant) and carboxyl-terminal (constant) halves. J Biol Chem. 1969 Jun 25;244(12):3393–3404. [PubMed] [Google Scholar]
  30. Solomon A., Weiss D. T., Kattine A. A. Nephrotoxic potential of Bence Jones proteins. N Engl J Med. 1991 Jun 27;324(26):1845–1851. doi: 10.1056/NEJM199106273242603. [DOI] [PubMed] [Google Scholar]
  31. Solomon A., Weiss D. T., Macy S. D., Antonucci R. A. Immunocytochemical detection of kappa and lambda light chain V region subgroups in human B-cell malignancies. Am J Pathol. 1990 Oct;137(4):855–862. [PMC free article] [PubMed] [Google Scholar]
  32. Solomon A., Weiss D. T. Serologically defined V region subgroups of human lambda light chains. J Immunol. 1987 Aug 1;139(3):824–830. [PubMed] [Google Scholar]
  33. Stone M. J. Amyloidosis: a final common pathway for protein deposition in tissues. Blood. 1990 Feb 1;75(3):531–545. [PubMed] [Google Scholar]
  34. Zschiesche W., Jakob W. Pathology of animal amyloidoses. Pharmacol Ther. 1989;41(1-2):49–83. doi: 10.1016/0163-7258(89)90102-2. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES